Santhera Extends AGAMREE Distribution Deal with Biomedica into Central Asia and Caucasus — Santhera Pharmaceuticals Holding AG

Event summary

Santhera expands its exclusive distribution agreement with Biomedica for AGAMREE® (vamorolone) to include Georgia, Kazakhstan, Belarus, Azerbaijan, and Uzbekistan.
The deal covers approximately 2,000 Duchenne muscular dystrophy (DMD) patients in these new markets.
Biomedica will handle distribution while Santhera receives a percentage of net sales under the original agreement terms.
AGAMREE® is already approved in multiple regions including the U.S., EU, UK, Switzerland, China, Hong Kong, and Canada.

The big picture

Santhera's expansion with Biomedica underscores a strategic push to broaden AGAMREE®'s global footprint, particularly in regions with high unmet medical needs. This move aligns with industry trends where rare disease treatments are increasingly targeting underserved markets. The deal also highlights the growing importance of regional distribution partnerships for specialty pharmaceutical companies seeking to scale without heavy infrastructure investments.

What we're watching

Market Penetration: How effectively Biomedica can integrate AGAMREE® into healthcare systems with historically limited treatment options for DMD.
Revenue Growth: Whether the expanded distribution will significantly boost Santhera's revenue from AGAMREE® sales in these new markets.
Regulatory Compliance: The pace at which regulatory approvals and market access can be secured in each of the five additional countries.